U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H14F3N3O3
Molecular Weight 389.328
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLPG-0492

SMILES

CN1C(=O)N(C(=O)[C@@]1(CO)C2=CC=CC=C2)C3=CC=C(C#N)C(=C3)C(F)(F)F

InChI

InChIKey=VAJGULUVTFDTAS-GOSISDBHSA-N
InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23523664

GLPG-0492, an orally available selective androgen receptor modulator (SARM) was tested in a Phase I Proof of Mechanism study to assess the effect on muscle function in healthy volunteers. A biomarker effect similar to that of Oxandrolone was observed, but the data were insufficient for Galapagos to pursue GLPG-0492 further in cachexia, and further development of the compound was discontinued. GLPG-0492 is currently under development for musculo-skeletal diseases such as sarcopenia and Duchenne muscular dystrophy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2362 ng × h/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GLPG-0492 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4675 ng × h/mL
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLPG-0492 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.5 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GLPG-0492 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.2 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLPG-0492 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.
2013 Jun
Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization.
2014 Sep 3
Patents

Sample Use Guides

GLPG-0492 oral solution Multiple ascending doses once daily for 14 days, starting from 5 mg/day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
GLPG-0492
Common Name English
(-)-GLPG-0492
Code English
G 100192
Code English
BENZONITRILE, 4-((4S)-4-(HYDROXYMETHYL)-3-METHYL-2,5-DIOXO-4-PHENYL-1-IMIDAZOLIDINYL)-2-(TRIFLUOROMETHYL)-
Systematic Name English
4-((4S)-4-(HYDROXYMETHYL)-3-METHYL-2,5-DIOXO-4-PHENYL-1-IMIDAZOLIDINYL)-2-(TRIFLUOROMETHYL)BENZONITRILE
Systematic Name English
GLPG0492
Code English
DT-200
Code English
Code System Code Type Description
FDA UNII
8O59X1ACZT
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY
PUBCHEM
59317190
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY
DRUG BANK
DB12461
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY
SMS_ID
300000041491
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
GLPG-0492
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY GLPG0492 has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials. GLPG0492 is a new non-steroidal selective androgen receptor modulator that is currently under development for musculo-skeletal diseases such as sarcopenia and cachexia. In acute exhaustion tests, a surrogate of the 6-min walking test used in DMD patients, GLPG0492 preserved running performance, whereas vehicle- or comparator-treated animals showed a significant increase in fatigue (30-50%). GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis.
CAS
1215085-92-9
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545417
Created by admin on Sat Dec 16 10:39:51 GMT 2023 , Edited by admin on Sat Dec 16 10:39:51 GMT 2023
PRIMARY